Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.
Orexo has a number of development programs for new products. At present the focus is on Zubsolv™ (OX219) for the treatment of opioid dependence. A New Drug Application for Zubsolv was submitted to the U.S. Food and Drug Administration, FDA, in September 2012, and the estimated approval date is July 6, 2013.
Furthermore, the OX51 program for the treatment of acute episodes of intense pain is under development. The OX27 program for a new treatment of breakthrough pain in cancer patients is at present dormant.
Abstral® is a product that provides rapid relief of breakthrough pain in cancer patients. Orexo has the product rights to Abstral in the USA. In Europe and the rest of the world the rights have been transferred to the ProStrakan Group plc. Orexo’s Japanese partner Kyowa Hakko Kirin Co., Ltd. holds the rights for KW-2246 (Abstral) in Japan.
Edluar™ is a product for the treatment of short-term insomnia. The specialty pharma company Meda has a global license for Edluar.
Orexo also markets Diabact® UBT, Heliprobe® System and IRIS® through its subsidiary Kibion. These are used in the diagnosis of Helicobacter pylori, the bacterium that causes gastric ulcers.
The collaboration with Boehringer Ingelheim was initiated in 2005 with focus on specific inhibition of the formation of prostaglandin E2 (PGE2) in different disease processes. Boehringer Ingelheim has sole responsibility for all research and development and commercialization of future products in the OX-MPI project.
Development of OX17 for the treatment of gastroesophageal reflux disease has been taking place in collaboration with Novartis since 2009.